miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 22, 2026

Crypto News: Pepeto Announces Exchange Upgrade While XRP Price Prediction Targets New ATH and Trump Iran War Shakes Crypto Markets

View original at globenewswire.com

Crypto News: Pepeto Announces Exchange Upgrade While XRP Price Prediction Targets New ATH and Trump Iran War Shakes Crypto Markets Dubai, UAE, March 22, 2026 (GLOBE NEWSWIRE) -- The Pepeto team just announced a new security upgrade on the exchange, adding stronger AI checks on the bridge and swap tools that work across…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Analysts see $5 as the floor target for XRP and some go as high as $10 once the CLARITY Act passes its March 27 review and ETF money has a clear path to enter
60% confidence
$466 million in trades went into forced closing across the crypto market after Trump threatened strikes on Iranian oil
60% confidence
Goldman Sachs is adding to its XRP position
60% confidence
Ripple spent $2.4 billion on deals over the past year that built the kind of setup big money needs to come in
60% confidence
War spending and oil problems raise the chance of rate cuts, and rate cuts are the one thing that has started every crypto bull run in history
60% confidence
BTC has made a higher low after every war headline since the fighting started
60% confidence

Data points we hold from this source

XRP · daily transactions

2.7 USD

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com